Search hospitals > Louisiana > New Orleans

University Medical Center New Orleans

Claim this profile
New Orleans, Louisiana 70112
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
255 reported clinical trials
30 medical researchers
Photo of University Medical Center New Orleans in New OrleansPhoto of University Medical Center New Orleans in New OrleansPhoto of University Medical Center New Orleans in New Orleans

Summary

University Medical Center New Orleans is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Breast cancer, Cancer and other specialties. University Medical Center New Orleans is involved with conducting 255 clinical trials across 464 conditions. There are 30 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Agustin Garcia, M.D..

Area of expertise

1Parotid Gland Cancer
Global Leader
University Medical Center New Orleans has run 79 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
University Medical Center New Orleans has run 54 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
HER2 positive

Top PIs

Clinical Trials running at University Medical Center New Orleans

Breast Cancer
Ovarian Cancer
Lung Cancer
Parotid Gland Cancer
Breast cancer
Cancer
Squamous Cell Carcinoma
Skin Cancer
Liver Cancer
Endometrial Cancer
Image of trial facility.

Giredestrant + Hormone Therapy

for Early-Stage Breast Cancer

This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University Medical Center New Orleans?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security